Cyclic TMTP1 polypeptide ligand radioactive probe as well as preparation method and application thereof

By developing a circular TMTP1 polypeptide ligand radioprobe, the problem of insufficient resolution and specificity of existing cancer diagnosis methods is solved, efficient and safe tumor imaging is achieved, and early diagnosis and higher therapeutic effects are provided.

CN119060140APending Publication Date: 2024-12-03THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411231221.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-04
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing cancer diagnosis methods have problems with limited resolution, specificity and sensitivity, and it is difficult to detect small lesions in the early stage and misdiagnosis or misdiagnosis. The existing molecular imaging agents also have shortcomings in selectivity, stability and toxicity.

Method used

Develop a circular TMTP1 polypeptide ligand radioprobe, synthesize cyclic TMTP1 polypeptide by solid-phase polypeptide synthesis method, and modify it using NOTA-NHS activated ester to label radionuclides to form a circular TMTP1 polypeptide ligand radioprobe , used to specifically target highly metastatic tumors.

Benefits of technology

Improves the stability and specific targeting ability of peptide ligands, simplifies the radiolabeling process, reduces renal intake, improves the accuracy and safety of diagnosis, and can be used to diagnose highly metastatic tumors in the early stage, providing earlier the opportunity for treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060140A_ABST
    Figure CN119060140A_ABST
Patent Text Reader

Abstract

The structural formula of the cyclic TMTP1 polypeptide ligand is Cyclo [K (NOTA) NVvRQ], the cyclic TMTP1 polypeptide ligand is structurally modified, after radiolabeling, the biological activity of the cyclic TMTP1 polypeptide ligand is not affected, the labeling method is simple, the labeling yield is high, and the cyclic TMTP1 polypeptide ligand has the biological characteristic of specifically targeting a high metastatic tumor and can be used for early diagnosis of the high metastatic tumor.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a cyclic TMTP1 polypeptide ligand radioactive probe and a preparation method and application thereof, belonging to the technical field of pharmaceutical chemistry. Background Art

[0002] Cancer is one of the diseases with the highest morbidity and mortality rates worldwide. Due to its unclear early symptoms, many patients are already in the late stage when diagnosed and miss the best treatment opportunity. Therefore, early diagnosis is crucial to improve the survival rate of cancer patients.

[0003] Existing cancer diagnosis methods mainly include ultrasound, CT, MRI and serum marker detection. However, these methods have certain limitations. For example, the resolution of imaging examinations is limited, making it difficult to detect early tiny lesions; the specificity and sensitivity of serum marker detection are insufficient, which may lead to misdiagnosis or missed diagnosis.

[0004] In recent years, molecular imaging technology has attracted widespread attention due to its ability to achieve early detection and precise positioning of diseases. Molecular imaging agents are a class of molecules that can specifically recognize and bind to tumor cells. When used in combination with imaging equipment, they can monitor the distribution and dynamic changes of tumors in the body in real time. However, existing molecular imaging agents still have deficiencies in selectivity, stability, toxicity, etc., and there is an urgent need to develop new tumor imaging agents to improve the accuracy and safety of diagnosis.

[0005] Peptide small molecules have become ideal candidates for tumor imaging agents due to their high biocompatibility, low toxicity and easy modification. In recent years, researchers have been committed to developing new peptide small molecules that can specifically identify cancer cells in order to improve the early diagnosis rate and treatment effect of cancer. However, current research is still in its initial stage and no mature products have yet been launched. Summary of the invention

[0006] The present invention provides a cyclic TMTP1 polypeptide ligand radioactive probe and a preparation method and application thereof, which can effectively solve the above problems.

[0007] The present invention is achieved in that:

[0008] A cyclic TMTP1 polypeptide ligand, the structural formula of which is:

[0009]

[0010] A method for synthesizing the above-mentioned cyclic TMTP1 polypeptide ligand is to synthesize the cyclic TMTP1 modified polypeptide according to the solid phase polypeptide synthesis method, and modify it using NOTA-NHS activated ester to obtain the obtained polypeptide.

[0011] A cyclic TMTP1 polypeptide ligand radioactive probe is obtained by labeling the above-mentioned cyclic TMTP1 polypeptide ligand with a radioactive nuclide.

[0012] In some embodiments, the radionuclide is 68 Ga, 18 F. 64 Cu, 177 Lu, 123 I. 11 C. 99m One or more of Tc.

[0013] A method for preparing the above-mentioned cyclic TMTP1 polypeptide ligand radioactive probe is to mix the cyclic TMTP1 polypeptide ligand solution with the radionuclide solution, and react them at a temperature of 90-100° C. for 10-20 minutes to obtain the probe.

[0014] In some embodiments, the cyclic TMTP1 polypeptide ligand solution is formed by dissolving the cyclic TMTP1 polypeptide ligand in sodium acetate buffer.

[0015] In some embodiments, the radionuclide solution is a hydrochloric acid eluent of the radionuclide.

[0016] A tumor imaging agent comprises the above-mentioned cyclic TMTP1 polypeptide ligand radioactive probe.

[0017] In some embodiments, the tumor is liver cancer.

[0018] A tumor diagnosis kit comprises the above-mentioned cyclic TMTP1 polypeptide ligand radioactive probe.

[0019] The beneficial effects of the present invention are:

[0020] The present invention relates to a cyclic TMTP1 polypeptide ligand, which forms a ring structure in a head-to-tail manner. By structurally modifying the TMTP1 (NVvRQ) sequence, the present invention ensures that its biological activity remains unchanged after radioactive labeling. The design of this ring structure not only improves the stability of the polypeptide ligand, but also may enhance its affinity with the target molecule.

[0021] The cyclic TMTP1 polypeptide ligand of the present invention adopts a simple method when labeling radionuclides, so that the entire labeling process is easy to realize automated synthesis. This method not only improves the labeling yield, but also the labeled product can be used directly without further purification. This is particularly important for those radionuclides with short half-lives, because they have a limited existence time in the body. The fast and efficient labeling process can ensure that the radiolabeled compounds have more advantages in commercial applications and clinical promotion.

[0022] The cyclic TMTP1 polypeptide ligand radioactive probe of the present invention has the biological property of specifically targeting highly metastatic tumors. This means that the probe can be used for early diagnosis of highly metastatic tumors, thereby providing patients with earlier treatment opportunities and improving treatment effects. This specific targeting ability is achieved by binding of the polypeptide ligand to specific receptors on the surface of tumor cells, so that the radioactive probe can accurately locate the tumor tissue.

[0023] The cyclic TMTP1 polypeptide ligand radioactive probe of the present invention has excellent pharmacokinetic properties. Under the premise of ensuring that the absolute value of tumor uptake and the tumor / liver uptake ratio remain unchanged, the kidney uptake is lower. This feature makes the probe more advantageous in clinical applications, because lower kidney uptake can reduce the radioactive exposure of the kidney and reduce the potential toxicity risk, thereby improving the safety of patients and the feasibility of treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments will be briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without paying creative work.

[0025] Figure 1 In the embodiment of the present invention, 68 The radiochemical purity of Ga]-Cyclo[K(NOTA)NVvRQ] was determined by HPLC.

[0026] Figure 2 In the embodiment of the present invention, 68 MicroPET imaging of Ga]-Cyclo[K(NOTA)NVvRQ] in nude mice bearing liver cancer (SMMC-7721) at 30 min.

[0027] Figure 3 For the comparative example of the present invention [ 68 The radiochemical purity of Ga]-Cyclo[K(NOTA)NVVRQ] was determined by HPLC.

[0028] Figure 4 For the comparative example of the present invention [ 68 MicroPET imaging of Ga]-Cyclo[K(NOTA)NVVRQ] in nude mice bearing liver cancer (SMMC-7721) at 30 min.

[0029] Figure 5 For the comparative example of the present invention [ 68The radiochemical purity of Ga]-Cyclo[K(NOTA)NVvRQ]2 was determined by HPLC.

[0030] Figure 6 For the comparative example of the present invention [ 68 MicroPET imaging of Ga]-Cyclo[K(NOTA)NVvRQ]2 in nude mice bearing liver cancer (SMMC-7721) at 30 minutes.

[0031] Figure 7 For the embodiments of the present invention and the comparative examples [ 68 Ga]-Cyclo[K(NOTA)NVVRQ],[ 68 Ga]-Cyclo[K(NOTA)NVvRQ],[ 68 Statistical graph of microPET images of Ga]-Cyclo[K(NOTA)NVvRQ]2 in nude mice bearing liver cancer (SMMC-7721) at 30 minutes.

[0032] Figure 8 For the embodiment of the present invention [ 68 In vitro stability diagram of Ga]-Cyclo[K(NOTA)NVvRQ].

[0033] Fig. 9 For the embodiment of the present invention [ 68 In vivo stability diagram of Ga]-Cyclo[K(NOTA)NVvRQ].

[0034] Fig.10 For the embodiment of the present invention [ 68 In vitro stability of Ga]-Cyclo[K(NOTA)NVVRQ]

[0035] Fig.11 For the embodiment of the present invention [ 68 In vivo stability diagram of Ga]-Cyclo[K(NOTA)NVVRQ].

[0036] Fig.12 For the embodiment of the present invention [ 68 In vitro stability diagram of Ga]-Cyclo[K(NOTA)NVvRQ]2.

[0037] Fig.13 For the embodiment of the present invention [ 68 In vivo stability diagram of Ga]-Cyclo[K(NOTA)NVvRQ]2. DETAILED DESCRIPTION

[0038] In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention. Therefore, the following detailed description of the embodiments of the present invention provided in the drawings is not intended to limit the scope of the invention claimed for protection, but merely represents the selected embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0039] The present invention provides a cyclic TMTP1 polypeptide ligand, the structural formula of which is:

[0040]

[0041] In an embodiment of the present invention, the cyclic TMTP1 polypeptide ligand polypeptide is a cyclic peptide obtained by cyclization modification. Compared with non-cyclic peptides, cyclic peptides exhibit multiple advantages. First, the structure of cyclic peptides is more stable than that of linear peptides, and can effectively resist enzymatic hydrolysis and chemical degradation in vivo and in vitro, thereby significantly improving its half-life and stability in vivo. This advantage enables cyclic peptides to maintain effective concentrations in vivo for a longer period of time, reduce the frequency of drug administration, and enhance the therapeutic effect. In addition, cyclization modification allows the polypeptide to form a stable three-dimensional structure, thereby better binding to the target, significantly improving the specificity and affinity of the polypeptide. This highly specific binding helps to reduce nonspecific effects and reduce the side effects of drugs.

[0042] Cyclization modification not only improves the stability of peptides, but also improves their bioavailability. Due to the enhanced stability of the cyclic peptide structure, its degradation rate in the body is slowed down, allowing the concentration of cyclic peptides in the blood to be maintained at a high level. This feature makes cyclic peptide drugs have better bioavailability and can exert a more lasting therapeutic effect in the body. In addition, some cyclic peptides have a higher cell penetration ability and can more effectively enter the cell to exert their effects, thereby improving the therapeutic effect.

[0043] Cyclization modification can also reduce the immunogenicity of peptides. Peptides usually trigger an immune response in the body, but cyclization modification can hide certain immunogenic regions of the peptide, thereby reducing its likelihood of triggering an immune response and improving its tolerance and safety in the body.

[0044] Cyclic peptides also have a diverse design space, and can be used through various chemical modifications and structural optimizations to design peptide molecules for different targets and uses, with a high degree of flexibility.

[0045] In this embodiment, the biological activity of the cyclic peptide is not affected after being radioactively labeled, and it has the biological property of specifically targeting highly metastatic tumors, and can be used for the early diagnosis of highly metastatic tumors.

[0046] In summary, cyclic peptides can greatly improve the effectiveness and safety of peptide drugs and diagnostic reagents through their significant advantages in stability, specificity, affinity and pharmacokinetic properties.

[0047] The embodiments of the present invention provide a method for synthesizing a specific cyclic TMTP1 polypeptide ligand. Specifically, the method follows the conventional steps of solid-phase polypeptide synthesis, and first synthesizes the desired cyclic TMTP1 modified polypeptide. In this process, the researchers connect various amino acids according to a predetermined sequence to form the desired polypeptide chain. Subsequently, in order to further modify and enhance the performance of the polypeptide, the researchers used a compound called NOTA-NHS activated ester for modification. Through this modification, the end or side chain of the polypeptide can be effectively functionalized, thereby giving the polypeptide new biological activity or enhancing its original biological activity. Finally, through this method, the desired cyclic TMTP1 polypeptide ligand was successfully prepared.

[0048] The embodiment of the present invention provides a cyclic TMTP1 polypeptide ligand radioactive probe, which is prepared by labeling a radionuclide onto a cyclic TMTP1 polypeptide ligand. This small molecule polypeptide cyclic TMTP1 polypeptide ligand labeled with a radionuclide can target tumor tissue in vivo and emit a detectable signal. By utilizing the radiation signal of the radionuclide, this probe can achieve high-sensitivity and high-resolution imaging, thereby facilitating early localization and diagnosis of tumors.

[0049] In some specific embodiments, the radionuclide used may be 68 Ga, 18 F. 64 Cu, 177 Lu, 123 I. 11 C. 99m One or more of Tc. Each of these radionuclides has its own unique physical and chemical properties, which makes them have different application values ​​in medical imaging. For example, 68 Ga and 18 F is commonly used in positron emission tomography (PET), while 99m Tc is widely used in single photon emission computed tomography (SPECT). By selecting the appropriate radionuclide, the performance of the probe can be optimized according to specific clinical needs and the characteristics of the imaging equipment, thereby improving the accuracy and efficiency of tumor diagnosis.

[0050] The embodiment of the present invention provides a method for preparing a cyclic TMTP1 polypeptide ligand radioactive probe. The method involves mixing a cyclic TMTP1 polypeptide ligand solution with a radionuclide solution and reacting under specific temperature and time conditions to obtain the desired radioactive probe. Specifically, the cyclic TMTP1 polypeptide ligand is dissolved in an appropriate buffer to form a ligand solution. Then, the ligand solution is mixed with a hydrochloric acid eluent of the radionuclide. The mixed solution is reacted at a temperature of 90-100 degrees Celsius for 10-20 minutes. The cyclic TMTP1 polypeptide ligand radioactive probe prepared by this method can directly obtain a labeling solution with a radiochemical purity greater than 95.0% without further purification steps. Such a labeling solution can be directly applied to in vitro and in vivo experiments without the need for additional processing steps, which greatly simplifies the experimental process and improves the experimental efficiency.

[0051] In some specific embodiments, the cyclic TMTP1 polypeptide ligand solution is prepared by dissolving the cyclic TMTP1 polypeptide ligand in a sodium acetate buffer. This buffer provides a stable environment for the ligand, helps to maintain its structure and activity, thereby ensuring that high-quality radioactive probes can be obtained in subsequent labeling reactions. In addition, in certain embodiments, the radionuclide solution is prepared by using a hydrochloric acid eluent of the radionuclide. This eluent is generally used for the extraction and purification of radionuclides, ensuring the purity and activity of the nuclides, thereby helping to improve the labeling efficiency and specificity of the final radioactive probe.

[0052] By using the above method, a cyclic TMTP1 polypeptide ligand radioactive probe suitable for various biomedical research and clinical applications can be prepared efficiently and simply. This probe not only has high radiochemical purity, but can also be directly used in in vitro and in vivo experiments without the need for complex purification steps, greatly improving the convenience and reliability of the experiment.

[0053] The embodiment of the present invention provides an imaging agent for tumor imaging, which comprises a specific cyclic TMTP1 polypeptide ligand radioactive probe. The probe can specifically bind to a specific receptor on the surface of tumor cells, thereby achieving high sensitivity and high specificity imaging of tumors.

[0054] In certain specific embodiments, the tumor type involved is liver cancer. In this case, by using a specific probe, the researchers found that the probe showed a higher tumor / kidney ratio and tumor / liver ratio in an experimental model simulating liver cancer. This means that while the probe targets liver cancer tissue, the uptake of the probe into the kidney and liver is significantly reduced, thereby effectively reducing the problems of nephrotoxicity and hepatotoxicity.

[0055] The embodiment of the present invention also provides a tumor diagnosis kit, which also contains the above-mentioned cyclic TMTP1 polypeptide ligand radioactive probe. This kit can be conveniently used for clinical diagnosis, and the presence and distribution of tumors can be detected by imaging technology, providing important diagnostic basis for doctors. The use of this kit not only improves the accuracy of tumor diagnosis, but also brings a more convenient diagnostic experience to patients.

[0056] Example 1

[0057] (1) Preparation of Cyclo[K(NOTA)NVvRQ]

[0058] Using an automatic peptide synthesizer and in accordance with the standard solid-phase peptide synthesis method, the peptide Cyclo[KNVvRQ] (customized at a Chinese peptide company) modified with D amino acids and a single ring was synthesized using solid-phase synthesis technology.

[0059] 30 mg of the polypeptide Cyclo[KNVvRQ] was dissolved in 1 mL of DMF (dimethylformamide), 50 mg of 1,4-diacetic acid-1,4,7-triazacyclononane-7-acetic acid-N-hydroxysuccinimide ester (NOTA-NHS ester, purchased from CheMatech) was added, and then DIEA (N,N-diisopropylethylamine) was added to adjust the pH to 8.0-8.5, and stirred at room temperature overnight. The mixture was separated and purified by HPLC, and the fractions of the target product were collected, combined and freeze-dried to obtain the target product Cyclo[K(NOTA)NVvRQ], which was confirmed by mass spectrometry analysis.

[0060] Cyclo[K(NOTA)NVvRQ],m / z:505.76([M+2H] + )

[0061] Its structural formula is:

[0062]

[0063] (2) Preparation 68 Ga hydrochloric acid aqueous solution: Use 4mL 0.05M hydrochloric acid to elute the Ge-68 / Ga-68 generator. 68 Aqueous solution of Ga in hydrochloric acid.

[0064] (3) Preparation 68Ga]-Cyclo[K(NOTA)NVvRQ]: Add 30μg Cyclo[K(NOTA)NVvRQ] to a 5mL sterile lyophilized bottle, then add 1mL 0.25M sodium acetate buffer to dissolve, and then add 2mL 68Ga hydrochloric acid eluent (30-40mCi). After the mixture is shaken, react at 95℃ for 15min, cool to room temperature, and determine its labeling rate by HPLC.

[0065] (4) Test 68 The radiochemical purity (RCP) of Ga]-Cyclo[K(NOTA)NVvRQ] was 98.46% ( Figure 1 ).

[0066] Depend on Figure 1 It can be seen that 68 The peak time of [Ga]-Cyclo[K(NOTA)NVvRQ] was about 10.06min.

[0067] Comparative Example 1

[0068] (1) Preparation of NOTA-G-NVvRQ

[0069] Using an automatic peptide synthesizer and following the standard solid-phase peptide synthesis method, G-NVvRQ (customized at a Chinese peptide company) without cyclization modification was synthesized using solid-phase synthesis technology.

[0070] 30 mg of polypeptide G-NVvRQ was dissolved in 1 mL of DMF (dimethylformamide), 50 mg of 1,4-diacetic acid-1,4,7-triazacyclononane-7-acetic acid-N-hydroxysuccinimide ester (NOTA-NHS ester, purchased from CheMatech) was added, and then DIEA (N,N-diisopropylethylamine) was added to adjust the pH to 8.0-8.5, and stirred at room temperature overnight. The mixture was separated and purified by HPLC, and the fractions of the target product were collected, combined and freeze-dried to obtain the target product NOTA-G-NVvRQ, which was confirmed by mass spectrometry analysis.

[0071] MS,m / z:958.19([M+H] +

[0072] Its structural formula is:

[0073]

[0074] (2) Preparation 68 Ga hydrochloric acid eluent: Use 4 mL of 0.05 M hydrochloric acid to elute the Ge-68 / Ga-68 generator to obtain 68 Ga hydrochloric acid eluent.

[0075] (3) Preparation 68 Ga-NOTA-G-NVvRQ: Add 30 μg NOTA-G-NVvRQ to a 5 mL sterile lyophilized bottle, then add 1 mL 0.25 M sodium acetate buffer to dissolve, and then add 2 mL 68 Ga hydrochloric acid eluent (30-40 mCi). After the mixture is shaken, react at 95°C for 15 minutes, cool to room temperature, and determine the labeling rate by HPLC.

[0076] (4) Testing 68 The radiochemical purity (RCP) of Ga-NOTA-G-NVvRQ is greater than 95%.

[0077] Comparative Example 2

[0078] (1) Preparation of Cyclo[K(NOTA)NVVRQ]

[0079] Cyclo[KNVVRQ] (customized at a Chinese peptide company) that had undergone single-ring modification but not D-amino acid modification was synthesized using solid-phase synthesis technology using an automatic peptide synthesizer and in accordance with standard solid-phase peptide synthesis methods.

[0080] 30 mg of the polypeptide Cyclo[KNVVRQ] was dissolved in 1 mL of DMF (dimethylformamide), 50 mg of 1,4-diacetic acid-1,4,7-triazacyclononane-7-acetic acid-N-hydroxysuccinimide ester (NOTA-NHS ester, purchased from CheMatech) was added, and then DIEA (N,N-diisopropylethylamine) was added to adjust the pH to 8.0-8.5, and stirred at room temperature overnight. The mixture was separated and purified by HPLC, and the fractions of the target product were collected, combined and freeze-dried to obtain the target product Cyclo[K(NOTA)NVVRQ], which was confirmed by mass spectrometry analysis.

[0081] Cyclo[K(NOTA)NVVRQ],m / z:1011.30([M+H]+)

[0082] Its structural formula is:

[0083]

[0084] (2) Preparation 68 Ga hydrochloric acid aqueous solution: Use 4 mL of 0.05 M hydrochloric acid to elute the Ge-68 / Ga-68 generator. 68 Aqueous solution of Ga in hydrochloric acid.

[0085] (3) Preparation 68Ga]-Cyclo[K(NOTA)NVVRQ]: Add 30 μg Cyclo[K(NOTA)NVVRQ] to a 5 mL sterile lyophilized vial, then add 1 mL 0.25 M sodium acetate buffer to dissolve, and then add 2 mL 68 The mixture was shaken and reacted at 95°C for 15 minutes, cooled to room temperature, and the labeling rate was determined by HPLC.

[0086] (4) Test 68 The radiochemical purity (RCP) of Ga]-Cyclo[K(NOTA)NVVRQ] is 98.87% ( Figure 3 ).

[0087] Depend on Figure 3 It can be seen that 68 The peak time of [Ga]-Cyclo[K(NOTA)NVVRQ] was about 10.09 min.

[0088] Comparative Example 3

[0089] (1) Preparation of Cyclo[K(NOTA)NVvRQ]2

[0090] Using an automatic peptide synthesizer and following the standard solid-phase peptide synthesis method, the bicyclic modified Cyclo[KNVvRQ]2 (customized at a Chinese peptide company) was synthesized using solid-phase synthesis technology.

[0091] 30 mg of the polypeptide Cyclo[KNVvRQ]2 was dissolved in 1 mL of DMF (dimethylformamide), 50 mg of 1,4-diacetic acid-1,4,7-triazacyclononane-7-acetic acid-N-hydroxysuccinimide ester (NOTA-NHS ester, purchased from CheMatech) was added, and then DIEA (N,N-diisopropylethylamine) was added to adjust the pH to 8.0-8.5, and stirred at room temperature overnight. The mixture was separated and purified by HPLC, and the fractions of the target product were collected, combined and freeze-dried to obtain the target product Cyclo[K(NOTA)NVvRQ]2, which was confirmed by mass spectrometry analysis.

[0092] Cyclo[K(NOTA)NVvRQ]2,m / z:923.90([M+2H] + )

[0093] Its structural formula is as follows:

[0094]

[0095] (2) Preparation 68Ga hydrochloric acid aqueous solution: Use 4mL 0.05M hydrochloric acid to elute the Ge-68 / Ga-68 generator. 68 Aqueous solution of Ga in hydrochloric acid.

[0096] (3) Preparation 68 Ga]-Cyclo[K(NOTA)NVvRQ]2: Add 30μg NOTA-G-NVvRQ to a 5mL sterile lyophilized bottle, then add 1mL 0.25M sodium acetate buffer to dissolve, and then add 2mL 68Ga hydrochloric acid eluent (30-40mCi). After the mixture is shaken, react at 95℃ for 15min, cool to room temperature, and determine its labeling rate by HPLC.

[0097] (4) Test 68 The radiochemical purity (RCP) of Ga]-Cyclo[K(NOTA)NVvRQ]2 is 99.91% ( Figure 5 ).

[0098] Depend on Figure 5 It can be seen that 68 The peak time of [Ga]-Cyclo[K(NOTA)NVvRQ]2 was about 10.95min.

[0099] Test Example 1: microPET imaging test

[0100] Nude mice bearing SMMC-7721 liver cancer (purchased from Shanghai Slake Laboratory Animal Co., Ltd. on May 10, 2024) were injected with 0.1 ml of the drug through the tail vein under anesthesia. 68 Ga-NOTA-G-NVvRQ, [ 68 Ga]-Cyclo[K(NOTA)NVVRQ],[ 68 Ga]-Cyclo[K(NOTA)NVvRQ],[ 68 Ga]-Cyclo[K(NOTA)NVvRQ]2 (about 7.4 MBq), and continuous dynamic microPET / CT tomography (Siemens Inveon) was performed for 30 min from 15 min to 45 min after injection. Figure 2 , 4, 6. After image acquisition, spatial reconstruction was performed using the 3D SPMAP algorithm. In the decay-corrected coronal image, the regions of interest (ROI) of tumors, normal tissues, and organs were circled, and the tumor uptake ID% / g, tumor / non-tumor (T / NT) ratios in the tumor model were calculated: including tumor / liver, tumor / muscle, tumor / kidney, etc. The results are shown in Figure 7 And as shown in Table 1.

[0101] The tumor uptake values ​​of the probe were compared at 15min, 30min, 45min and 60min. 68 Compared with 0.93±0.10, 0.71±0.15, 0.58±0.22 and 0.52±0.13%ID / g of [ 68 The tumor uptake values ​​of Ga]-Cyclo[K(NOTA)NVvRQ] were 1.05±0.17, 0.82±0.10, 0.75±0.13 and 0.59±0.08%ID / g, respectively. 68 The tumor uptake values ​​of Ga]-Cyclo[K(NOTA)NVvRQ] at each time point increased. It is particularly noteworthy that compared with [ 68 Ga]-Ga-NOTA-G-NVvRQ, [ 68 Ga]-Cyclo[K(NOTA)NVvRQ] always showed a relatively low renal uptake, and the tumor / kidney ratio increased from 0.35±0.07, 0.71±0.12, 0.92±0.31 and 0.82±0.18 to 0.65±0.24, 0.84±0.27, 1.07±0.44 and 1.11±0.31 at each time point, respectively, and the area under the renal uptake-time curve decreased by 7.40%.

[0102] The tumor uptake values ​​of the probes were compared at 15min, 30min, 45min, and 60min. 68 The uptake of Ga]-Cyclo[K(NOTA)NVvRQ] was 1.05±0.17, 0.82±0.10, 0.75±0.13, and 0.59±0.08%ID / g, [ 68 The tumor uptake values ​​of Ga]-Cyclo[K(NOTA)NVVRQ] were 1.04±0.07, 0.89±0.06, 0.76±0.07 and 0.69±0.05%ID / g, respectively. 68The tumor uptake values ​​of Ga]-Cyclo[K(NOTA)NVVRQ] at each time point were almost the same. 68 The uptake of [Ga]-Cyclo[K(NOTA)NVvRQ] in the kidney was particularly reduced. 68 Ga]-Cyclo[K(NOTA)NVVRQ] consistently showed relatively high renal uptake, [ 68 The tumor / kidney ratios of Ga]-Cyclo[K(NOTA)NVVRQ] probe at each time point were 0.32±0.06, 0.52±0.09, 0.57±0.02, and 0.57±0.14, respectively, while the D-amino acid modified [ 68 Ga]-Cyclo[K(NOTA)NVvRQ] probe, the tumor / kidney ratios at each time point were 0.65±0.24, 0.84±0.27, 1.07±0.44, and 1.11±0.31, respectively, and the area under the kidney uptake-time curve increased by more than 74.09%.

[0103] The tumor uptake values ​​of the probe were compared at 15min, 30min, 45min and 60min. 68 The %ID / g of [Ga]-Ga-NOTA-G-NVvRQ was 0.93±0.10, 0.71±0.15, 0.58±0.22 and 0.52±0.13%ID / g, respectively. 68 Compared with 1.05±0.17, 0.82±0.10, 0.75±0.13 and 0.59±0.08%ID / g of [ 68 The tumor uptake values ​​of Ga]-Cyclo[K(NOTA)NVvRQ]2 were 0.96±0.12, 0.77±0.08, 0.69±0.06 and 0.54±0.22%ID / g, respectively. 68 Ga]-Cyclo[K(NOTA)NVvRQ] 2、 Uncyclized 68 Ga]-Ga-NOTA-G-NVvRQ and [ 68 The tumor uptake values ​​of Ga]-Cyclo[K(NOTA)NVvRQ] at each time point were almost the same, indicating that simply increasing the degree of cyclization cannot significantly increase the uptake of the probe in the tumor. 68 Ga]-Ga-NOTA-G-NVvRQ and [ 68 Compared with [Ga]-Cyclo[K(NOTA)NVvRQ], 68Ga]-Cyclo[K(NOTA)NVvRQ]2 always showed very high renal uptake, and the tumor / kidney ratios of the three probes at each time point were 0.35±0.07, 0.71±0.12, 0.92±0.31, 0.82±0.18 and 0.65±0.24, 0.84±0.27, 1.07±0.44, 1.11±0.31, respectively, and 0.25±0.04, 0.37±0.05, 0.41±0.05, 0.43±0.07, respectively. The areas under the renal uptake-time curves increased by 84.20% and 98.92%, respectively. It can be seen that the double-ring modified [ 68 Ga]-Cyclo[K(NOTA)NVvRQ]2 and uncyclized [ 68 Ga]-Ga-NOTA-G-NVvRQ and only single ring modified [ 68 Compared with Ga]-Cyclo[K(NOTA)NVvRQ], the tumor uptake was almost the same, but the D-amino acid modified and single-ring modified [ 68 The renal uptake of Ga]-Cyclo[K(NOTA)NVvRQ] was the lowest.

[0104] The same analysis showed that the D amino acid modified and single ring modified [ 68 The uptake in liver and heart of Ga]-Cyclo[K(NOTA)NVvRQ] was also the lowest.

[0105] Table 1 Organ distribution and target-non-target ratio of each probe at different time points

[0106]

[0107]

[0108]

[0109]

[0110] Test Example 2: Stability Test

[0111] In vitro stability test: 100 μCi of [ 68 Ga]-Cyclo[K(NOTA)NVvRQ],[ 68 Ga]-Cyclo[K(NOTA)NVVRQ] and [ 68Ga]-Cyclo[K(NOTA)NVvRQ]2 was co-incubated in equal volumes of saline and serum at 37°C for 60 min and 120 min. After the time, the saline group could be directly sampled and monitored for radiochemical purity by radio-HPLC. The serum group was precipitated with acetonitrile (containing 0.15% trifluoroacetic acid) and filtered before being directly sampled and monitored for radiochemical purity by radio-HPLC.

[0112] In vivo stability test: 100 μCi of [ 68 Ga]-Cyclo[K(NOTA)NVvRQ],[ 68 Ga]-Cyclo[K(NOTA)NVVRQ] and [ 68 Ga]-Cyclo[K(NOTA)NVvRQ]2 was injected into nude mice through the tail vein, and urine and blood were collected at 30min and 60min. The urine sample was filtered and directly injected to monitor the radiochemical purity by radio-HPLC. After the blood was centrifuged and the upper serum was taken, the protein was precipitated with acetonitrile (containing 0.15% trifluoroacetic acid), and the radiochemical purity was monitored by radio-HPLC after filtration.

[0113] [ 68 The in vitro stability of Ga]-Cyclo[K(NOTA)NVvRQ] Figure 8 As shown, the in vivo stability Fig. 9 shown.

[0114] [ 68 The in vitro stability of Ga]-Cyclo[K(NOTA)NVVRQ] Fig.10 As shown, the in vivo stability Fig.11 shown.

[0115] [ 68 The in vitro stability of Ga]-Cyclo[K(NOTA)NVvRQ]2 is shown in Fig.12 As shown, the in vivo stability Fig.13 shown.

[0116] The in vitro and in vivo stability results showed that [ 68 Ga]-Cyclo[K(NOTA)NVvRQ],[ 68 Ga]-Cyclo[K(NOTA)NVVRQ] and [ 68The three probes, Ga]-Cyclo[K(NOTA)NVvRQ]2, can be stably present in the injection storage medium for at least 120 minutes, and the radiochemical purity still meets the quality control requirements of radiopharmaceuticals. At the same time, the three probes also maintain high radiochemical purity for at least 60 minutes in the body, which ensures that each probe can better play a role in its original structure.

[0117] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A cyclic TMTP1 polypeptide ligand, characterized in that: Its structural formula is:

2. A method for synthesizing the cyclic TMTP1 polypeptide ligand according to claim 1, characterized in that: According to the solid phase peptide synthesis method, the cyclic TMTP1 modified peptide was synthesized and modified using NOTA-NHS activated ester to obtain the peptide.

3. A cyclic TMTP1 polypeptide ligand radioactive probe, characterized in that: The cyclic TMTP1 polypeptide ligand according to claim 1 is labeled with a radionuclide.

4. The cyclic TMTP1 polypeptide ligand radioactive probe according to claim 3, characterized in that: The radionuclide is 68 Ga, 18 F. 64 Cu, 177 Lu, 123 I. 11 C. 99m One or more of Tc.

5. A method for preparing the cyclic TMTP1 polypeptide ligand radioactive probe according to claim 3 or 4, characterized in that: The cyclic TMTP1 polypeptide ligand solution is mixed with the radioactive nuclide solution, and reacted at 90-100° C. for 10-20 minutes to obtain the product.

6. The preparation method according to claim 5, characterized in that: The cyclic TMTP1 polypeptide ligand solution is formed by dissolving the cyclic TMTP1 polypeptide ligand in a sodium acetate buffer.

7. The preparation method according to claim 5, characterized in that: The radionuclide solution is a hydrochloric acid eluent of the radionuclide.

8. A tumor imaging agent, characterized in that: The invention comprises the cyclic TMTP1 polypeptide ligand radioactive probe according to claim 3 or 4.

9. The tumor imaging agent according to claim 8, characterized in that The tumor is liver cancer.

10. A tumor diagnosis kit, characterized in that: The invention comprises the cyclic TMTP1 polypeptide ligand radioactive probe according to claim 3 or 4.